Research Center and Tumor Research Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
BMC Cancer. 2024 Aug 15;24(1):1014. doi: 10.1186/s12885-024-12771-z.
BACKGROUND: The prognosis nutritional index (PNI) and the systemic inflammatory immunological index (SII) are characteristic indicators of the nutritional state and the systemic inflammatory response, respectively. However, there is an unknown combined effect of these indicators in the clinic. Therefore, the practicality of using the SII-PNI score to predict prognosis and tumor response of locally advanced gastric cancer (LAGC) following chemotherapy was the main focus of this investigation. METHODS: We retrospectively analyzed 181 patients with LAGC who underwent curative resection after neoadjuvant chemotherapy in a prospective study (NCT01516944). We divided these patients into tumour regression grade(TRG) 3 and non-TRG3 groups based on tumor response (AJCC/CAP guidelines). The SII and PNI were assessed and confirmed the cut-off values before treatment. The SII-PNI values varied from 0 to 2, with 2 being the high SII (≥ 471.5) as well as low PNI (≤ 48.6), a high SII or low PNI is represented by a 1 and neither is represented by a 0, respectively. RESULTS: 51 and 130 samples had TRG3 and non-TRG3 tumor responses respectively. Patients with TRG3 had substantially higher SII-PNI scores than those without TRG3 (p < 0.0001). Patients with greater SII-PNI scores had a poorer prognosis (p < 0.0001). The SII-PNI score was found to be an independent predictor of both overall survival (HR = 4.982, 95%CI: 1.890-10.234, p = 0.001) and disease-free survival (HR = 4.763, 95%CI: 1.994-13.903, p = 0.001) in a multivariate analysis. CONCLUSION: The clinical potential and accuracy of low-cost stratification based on SII-PNI score in forecasting tumor response and prognosis in LAGC is satisfactory.
背景:预后营养指数(PNI)和全身炎症免疫指数(SII)分别是营养状态和全身炎症反应的特征指标。然而,这些指标在临床上的联合作用尚不清楚。因此,本研究主要关注 SII-PNI 评分在预测局部晚期胃癌(LAGC)化疗后预后和肿瘤反应中的实际应用。
方法:我们对 181 例接受新辅助化疗后行根治性切除术的 LAGC 患者进行了前瞻性研究(NCT01516944)。我们根据肿瘤反应(AJCC/CAP 指南)将这些患者分为肿瘤消退分级(TRG)3 组和非 TRG3 组。在治疗前评估 SII 和 PNI,并确定截断值。SII-PNI 值从 0 到 2 变化,2 表示高 SII(≥471.5)和低 PNI(≤48.6),高 SII 或低 PNI 表示为 1,两者均无表示为 0。
结果:51 例和 130 例患者的肿瘤反应分别为 TRG3 和非 TRG3。TRG3 患者的 SII-PNI 评分明显高于非 TRG3 患者(p<0.0001)。SII-PNI 评分较高的患者预后较差(p<0.0001)。多因素分析显示,SII-PNI 评分是总生存(HR=4.982,95%CI:1.890-10.234,p=0.001)和无病生存(HR=4.763,95%CI:1.994-13.903,p=0.001)的独立预测因子。
结论:SII-PNI 评分基于低成本分层在预测 LAGC 肿瘤反应和预后方面具有令人满意的临床潜力和准确性。
Medicina (Kaunas). 2025-1-24